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were $Brz674.527 for each 100 treated patients, when comparing the group of 
patients that received tocilizumab to the group of patients that did not receive tocili-
zumab. CONCLUSIONS: Findings suggest tocilizumab has the potential to offer costs 
reductions in the public health care system in Brazil.
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OBJECTIVES: To develop a cost-effectiveness and budget impact analysis of intra-
articular sodium hyaluronate 25 mg/2.5 ml (SH) versus total knee arthroplasty (TKA) 
in the treatment of knee osteoarthritis grades II and III of Kellgren-Lawrence classiﬁca-
tion, in patients who failed conservative treatment, under the Brazilian public health 
care system (BPHS) perspective. METHODS: A Markov model was developed to 
project costs and outcomes associated with knee osteoarthritis progression in 3 years. 
In the model all patients were eligible to surgery and could either receive SH or 
undergo TKA immediately. SH could delay or cancel surgery. The cycle duration was 
3 months and the corresponding transition probabilities were obtained from the litera-
ture. The outcome was expressed as the number of avoided TKAs. The analysis con-
sidered only direct medical costs, including drugs, physician visits, procedures and 
complications treatment. Costs and outcomes were discounted at 5% per year. A 
budget impact analysis was developed considering the estimated number of TKAs in 
the BPHS in 2009. Main parameters were evaluated in a sensitivity analysis. RESULTS: 
In a 3-year time horizon, total costs per patient were US$3445 (2005-PPP-index 
USD1.0  R$1.4) for the SH group and R$4381 for the TKA group. The reduction 
in the absolute number of surgeries was 72.8% in the SH group, compared with TKA. 
Likewise, there was a cost reduction of US$936, in favor of SH. Considering 3991 
eligible patients in the public system, the total annual costs for SH and TKA groups 
were US$5,136,234 and US$17,484,003, respectively. As a result, the budget impact 
was US$12,347,769, in favor of SH. The sensitivity analysis about the time horizon 
showed a cost-saving result until 4 years. CONCLUSIONS: The use of SH after failure 
of conservative treatment in patients with grades II or III knee osteoarthritis showed 
to be effective, leading to a reduction in costs and number of surgeries.
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OBJECTIVES: To estimate the budget impact implied by the introduction of RTX 
after failure of one or more TNF a therapies for the French health care system. 
METHODS: A Markov model reproduced the course, over 4 years, of patients treated 
by either inﬂiximab, etanercept, adalimumab or RTX, after failure of one or more 
TNF a therapies. Markov states were composed of the 4 TNF a strategies. The success 
rate for each strategy (ACR20) was based on a bayesian mixed treatment comparisons 
model.Health care consumptions were estimated from an observational study con-
ducted retrospectively in 59 hospital rheumatology services (TC2 study). Three 
hypotheses were tested for the penetration of RTX into the market: RTX is not used 
(H1), RTX is used progressively (H2), RTX is the only treatment available (H3). As a 
sensitivity analysis, we applied coefﬁcients to health care resources in third line. 
RESULTS: The RTX target population is expected to be 5700 patients. Under H1, 
direct total medical costs are expected to be a47,180,000. Under H3 these costs reach 
a32,600,000, thus a decrease of 31% respectively compared to H1. Under H2, costs 
progressively decreased as RTX penetrates the market. The impact of multiplication 
coefﬁcients is important. At the beginning of the simulation, the difference between 
the base-case analysis (H2) and the worst case sensitivity analysis (coeff2  20%) 
 concerning the total direct medical costs reached a3,160,000 (respectively a47,560,000 
for H2 and a50,720,000 for H2–20%). However, while RTX progressively enters into 
the market, this difference decreases, attaining only a1,175,000 at the end of the simu-
lation. CONCLUSIONS: RTX is expected to produce important savings if used after 
failure of one or more TNF a therapies. This is due to the administration rhythm of 
this product, generally every 6 to 12 months.
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OBJECTIVES: To estimate the annual direct and indirect costs of psoriatic arthritis 
(PsA) in Spain, and to identify key cost drivers. METHODS: An observational study 
was undertaken at 18 Spanish centres. Sociodemographic characteristics and duration 
of the disease were collected from patient hospital clinical records, and PsA-related 
resources (a, year 2008 values) from patient notebooks. The following direct resources 
were collected: inpatient hospitalisations, surgeries, outpatient visits (specialists, 
general care physician, other health care professionals and alternative medicine), 
diagnostic procedures, laboratory tests, medication (prescription -including TNFalpha 
inhibitors administered at hospital- and non-prescription drugs paid by patients), 
hospital day-care facilities for the administration of biological therapies and photo-
therapy sessions. Indirect resources consisted of productivity losses (full or part-time), 
social assistance and out-of-pocket expenses paid directly by patients (formal caregiv-
ers, disease-related investments). RESULTS: Data were available on 287 patients with 
PsA. The mean age was 52.40 o 12.53 years, 55.7% were men, and the mean disease 
duration was 10.85 o 9.62 years. Of these patients, 24.7% had received biologic 
therapy during the study period. The average annual cost per patient with PsA was 
a6710 (95% conﬁdence interval [CI], a4949, a8584). Direct and indirect costs repre-
sented a5449 (95%CI, a4367–a6597, 81.2% of total costs) and a1261 (95%CI, 
a581–a1987, 18.8% of total costs), respectively. The most important categories of 
costs were for medication (a3,758, 95%CI, a3,338–a4,241, 56.0% of total costs), 
productivity losses (a1121, 95%CI, a551–a1692, 16.7% of total costs), visits (a750, 
95%CI, a507–a943, 11.2% of total costs), and hospital day visits (a306, 95%CI, 
a289–a324, 4.6% of total costs). CONCLUSIONS: Our data show that psoriatic 
arthritis is associated with a remarkable impact over society in Spain, with a mean 
annual cost per patient of a6710. Direct costs represent 81.2% of total costs.
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OBJECTIVES: Neuromuscular disorders (NMDs) are chronic devastating diseases. 
The objective of this multicenter cross-sectional study was to evaluate cost of illness 
in three NMD in Germany. METHODS: A cohort of 107 patients with Amyotrophic 
Lateral Sclerosis (ALS, n  46), Facioscapulohumeral Muscular Dystrophy (FSHD, n 
 20) or Myasthenia Gravis (MG, n  41) were recruited consecutively in seven centers 
in Germany. The health-economic data were collected using a “bottom-up” approach 
consisting of comprehensive questionnaires and patient diaries. Bootstrap 95% conﬁ-
dence intervals were calculated for cost data. Cost-driving factors were identiﬁed using 
multivariate regression analysis with standard errors estimated using a bootstrap 
technique. Costs were evaluated from the German societal perspective in 2009 Euros 
(EUR). RESULTS: Total annual costs from the societal perspective were EUR 36,380 
(95% CI: 27,090–47,970) per patient in ALS, a26,240 (95% CI: 17,770–37,940) in 
FSHD and a14,950 (95% CI: 10,470–21,730) in MG. The main components of costs 
were the expenditures of health insurance and the loss of productivity of patients and 
their caregivers. Following independent cost-driving factors were identiﬁed in ALS: 
disease severity, assistance in activities of daily living (ADL), dementia and younger 
age. In FSHD, they were disease severity and assistance in ADL. Cost-drivers in MG 
were disease severity and assistance in ADL. CONCLUSIONS: Socioeconomic burden 
of NMDs in Germany is considerable. ALS was associated with highest costs among 
studied NMDs. Further studies evaluating both the health-economic and clinical 
effects of NMDs treatment as well as disease-management programs and benchmark-
ing activities are necessary.
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OBJECTIVES: Costs of Spina Biﬁda (SB) and of its prevention with folic acid have 
never been estimated in Italy. We carried out a 12-month observational multicentre, 
prospective, cost-of-illness study of the to assess direct and indirect costs of SB from 
the patient, the third-party payer (National Health Service- NHS) and the societal 
perspective. METHODS: A total of 130 patients were enrolled in this study and were 
eligible to be analyzed according to the study protocol during 2008. The study was 
conducted in three Italian centres (Milan, Rome and Parma). Inclusion criteria were: 
walking with motor impairment, walking with simple aid, walking with complex aid, 
non walking. Exclusion criteria were: patients with dorsal lesion up to D5/D6, patients 
with spina biﬁda aperta with severe comorbidity RESULTS: Mean age was 13 years 
(min.0 – max. 29 years). The mean total cost for SB, including direct and indirect 
items, was a11,351 per patient per year (58% direct cost and 42% on indirect cost). 
The cost of medical device for SB represents the most signiﬁcant item, accounting for 
38% of the total expenses. Difference on cost analysis was observed per age (a13,882 
for an age between 0–4 years), per SB severity (non walking,, a14,323) and per lesion 
(a12,103 for SB aperta). The average Cost-of-illness per year in Italy was evaluated 
in 60 million of euro. CONCLUSIONS: The estimate of the socio-economic burden 
of SP may encourage health care interventions to prevent the occurrence of the disease 
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and promote services and/or treatments. This study can also help to assess the cost-
beneﬁt ratio of folic acid supplementation and the cost-beneﬁt ratio of recommended 
food supplements.
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OBJECTIVES: Fibromyalgia or ﬁbromyalgia syndrome (FMS) is characterized by 
chronic widespread muscular pain and generalized tender points, often accompanied 
by a number of associated symptoms such as fatigue, sleep disturbance, psychological 
distress. The objective of this study was to assess the medical resource utilization 
(MRU) and workdays lost (WDL) of FMS patients according to the level of pain and 
fatigue. METHODS: The Adelphi Fibromyalgia Disease Speciﬁc Programme is a cross-
sectional survey among 2159 FMS patients in France, Germany, Italy, Spain and the 
UK. The survey included one questionnaire ﬁlled in by the patient and one by the 
physician. Patient health states were deﬁned on the basis of items 15 and 16 (100 mm 
VAS scales) of FIQ (Fibromyalgia Impact Questionnaire). RESULTS: From the pool 
of 2159 FMS patients, most patients with moderate pain (80.5%) or severe pain 
(95.5%) also suffered from fatigue. A total of 1341 patients had signiﬁcant fatigue 
(cut off: 50 mm), associated with mild (40 mm; N  154), moderate (40–70 mm; N 
 587) or severe (70 mm; N  600) pain. The annual number of physician visits per 
patient (5.71, 6.14 and 7.47 respectively), co-medication costs per 4 weeks (£3.66, 
£5.48 and £8.11), as well as the annual hospitalisation rate (2.6%, 5.6% and 7.5%) 
and length of stay per patient per year (0.42, 1.69 and 1.95 days, respectively) 
increased following the level of pain. Similarly, the percentage of patients on sick leave 
and its duration were larger in patients with fatigue and moderate (11.9% and 40 
weeks) or severe (20.0% and 44 weeks) pain, compared to patients with mild pain 
(8.4% and 33 weeks). CONCLUSIONS: In patients with FMS who present with sig-
niﬁcant fatigue, medical resource utilization and workdays lost are driven by the level 
of pain.
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OBJECTIVES: This review was performed to document and analyse the evolution of 
costs in Fibromyalgia (FM). METHODS: A systematic review (SR) was performed 
using Mesh terms (Medline 1980–2009). Articles on FM were selected if they pre-
sented direct or indirect costs. Two researchers extracted costs which were divided by 
type of resource. Total direct costs were divided by health care visits, hospitalization, 
procedures and drug costs; and, indirect costs in two types: absenteeism or work with 
reduced productivity. Costs were compared and differences were documented. Trends 
analysis was performed after converting results to USD$. RESULTS: Out of 28 cita-
tions, 7 articles were included. Four papers reported costs in USD$, 2 in Euros and 1 
in CA$. Costs were reported /patient/year, except for the Canadian 6-month study. 
All studies identiﬁed total direct costs, disaggregated in subtypes by 6 of them. Five 
studies reported total indirect costs; 3/5 reported on absenteeism and on reduced 
productivity. Three US studies were performed before 2000, and one in 2005. There 
was a progression in total direct costs/patient/yr from 1996 to 2005 from USD$2274 
to USD$7286 respectively and for total indirect costs, from USD$1010 to USD$2913. 
Two European analyses provided similar total direct costs/patient/yr, but did not 
report on the same indirect costs. The 6-month results were excluded from the primary 
trend analysis. A slope of y  1990x and R2  0.83 was obtained, showing a reliable 
increasing trend. Including the 6-month analysis (multiplied by 2), results changed to 
y  1881x, R2  0.64. CONCLUSIONS: This SR and trend analysis documented two 
major categories and subtypes of costs reported for FM, and detected an increasing 
trend. Limitations arose from adjusting indirect costs in two studies and the inclusion 
of papers from various settings. Further detailed analyses, including costs of comor-
bidities and premature death, are warranted to establish the full economic impact of 
FM.
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OBJECTIVES: The purpose of this analysis was to assess the direct and indirect costs 
of rheumatoid arthritis (RA) treatment in Poland in the years 2003–2007. METHODS: 
In order to estimate the direct medical costs of RA, including the costs of medical 
consultation, hospitalization, rehabilitation, drugs and diagnostic tests, data for the 
years 2004–2007 of the National Health Fund were used. Indirect costs like costs of 
pensions for incapacity for work, the costs of rehabilitation and social costs of rents 
for the years 2003–2007 were obtained from the Department of Social Security. 
RESULTS: Direct medical costs of RA in Poland ranged from 115.7 million pln in 
2004 to 126.5 million pln in 2007. Costs of hospital treatment amounted up to 70% 
of the direct costs in 2007. Indirect costs amounted to almost 60 million pln in 2003 
and rose to over 62 million pln in 2007. The largest share of these costs constitute 
the costs of pensions for incapacity for work, which share in indirect costs was 83% 
in 2007. Costs of rehabilitation were increasing in subsequent years (from around 4 
million in 2003 to 9.7 million pln in 2007). The total cost of treatment of RA showed 
an upward trend, reaching a value almost 177 million pln in 2004 and increased to 
almost 188 million pln in 2007. The total cost was dominated by the direct costs with 
share equal to 65% in 2004 to 66.8% in 2007 of the total costs. CONCLUSIONS: 
From year to year RA causes a growing economic burden on the health care and social 
insurance in Poland. The cost structure is dominated by the direct costs, which in turn 
largely consist of the costs of hospital treatment. Indirect costs are affected largely by 
rents due to the inability to work.
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OBJECTIVES: To estimate the costs savings in outpatient medical resource use associ-
ated with diagnosing ﬁbromyalgia during the four years after diagnosis in ﬁve European 
countries (UK, France, Italy, Spain, Germany). METHODS: The UK resource use data 
were extracted from medical records of 2,260 patients diagnosed with FM between 
1998 and 2003 in the General Practice Research Database (GPRD). For the others 
countries, a questionnaire was created based on the UK data and local experts, GP 
and rheumatologists, were asked to compare their own clinical practice to UK prescrip-
tions in terms of tests, drugs, general practitioners and specialists visits, over a period 
of 4 years before diagnosis to 4 years after the diagnosis. Medical resource use if 
diagnosis would not have been established was predicted using adapted published 
Poisson loglinear regression models. The observed and predicted trends in outpatient 
resource use and costs were calculated, so the impact of diagnosis could be evaluated 
for each of these medical resources. RESULTS: In the ﬁve countries studied, whereas 
costs are increasing during the years till diagnosis (40–72% in 4 years, a394a per 
patient the year of diagnosis from the health care perspective in Italy to a2108 in 
Germany), after diagnosis a decrease is observed (5–10%). Compared to a diagnosed 
FM patient, a non-diagnosed patient represents an incremental cost that ranges 
between 97a (Italy) and a421a (Spain) per patient and per year from the health care 
payer perspective. These higher costs are due to more GP and specialist visits and 
diagnostic tests. An earlier diagnosis allows from the societal perspective savings ranged 
from 106a (Italy) to a432 (Spain) per patient and per year. CONCLUSIONS: Making 
the diagnosis of FM reduces costs gradually independent of the country studied.
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OBJECTIVES: To compare the resource use and related costs associated with the 
management of ﬁbromyalgia (FM) in ﬁve European countries (UK, France, Italy, 
Spain, Germany). METHODS: The UK resource use data were extracted from medical 
records of 2,260 patients diagnosed with FM between 1998 and 2003 in the General 
Practice Research Database (GPRD). For the other countries, a questionnaire was 
created based on the UK data and local experts, GP and rheumatologists, were asked 
to compare their own clinical practice to UK prescriptions in terms of tests, drugs, 
general practitioners and specialists visits, over a period of 4 years before diagnosis 
to 4 years after the diagnosis. Information on paramedical and alternative care was 
also collected for France, Italy, Spain, Germany. Inpatient care and productivity loss 
were not included in GPRD and thus also not in the questionnaire. The public payer 
and societal perspective were used. RESULTS: Resource use and average costs related 
to lab tests per person-year from the public health care payer perspective were highest 
in Spain (101a) and the UK, the year of diagnosis and decrease afterwards (a69 in 
Spain). Drug costs are higher in Germany (a242a) mainly due to the higher unit costs. 
Costs related to GP visits increase till diagnosis in Germany (a892) and the UK. The 
costs for referrals to specialists are the highest before diagnosis in the UK (a131), 
France, and Italy. Overall, the highest mean annual total cost per patient from the 
societal perspective was found in Germany (a1,897), the lowest in Italy (a454). The 
highest patient contribution was seen in France (54%), the lowest in Italy (16%). 
CONCLUSIONS: Although moderate differences between countries were found in the 
management of FM, once a formal FM diagnosis was made, the resource use and costs 
decreased independent of the countries studied.
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OBJECTIVES: Balloon kyphoplasty (BKP) is a minimally invasive procedure for the 
treatment of painful vertebral compression fractures (VCFs). Superior clinical out-
comes data versus non surgical management (NSM) has recently been demonstrated 
in a large RCT comparing BKP and VCF. Furthermore, preliminary results of a large 
